Literature DB >> 7584871

Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study.

J K Saito1, J W Davis, R D Wasnich, P D Ross.   

Abstract

Although high doses of glucocorticoids are believed to cause bone loss, the effects of low glucocorticoid doses are still controversial. Our study examined the effects of low-dose glucocorticoids on the rate of bone loss at three appendicular bone sites. The study population was a cohort of elderly Japanese-Americans, 1094 women and 1378 men. The women were all postmenopausal. At the baseline examination the mean age of the women was 64 years (range 45-81), and the mean age of the men was 68 years (range 61-82). Glucocorticoid users (19 women and 21 men) had used oral systemic or inhaled glucocorticoids on a regular schedule for more than 1 month (mean use was 2.1 years for the women and 1.9 years for the men). The most common dose was equivalent to 5 mg/day of prednisone; fewer than 15% of users had taken doses equivalent to 10 mg/day or more. Changes in bone mass at the calcaneus, distal radius, and proximal radius were documented using bone densitometry at 1 to 2-year intervals over an 8-year period. The initial bone mass of the glucocorticoid users and controls was similar at the baseline examination. The subsequent loss rates among females during glucocorticoid use, however, were approximately double that of the controls. Among males, bone loss rates during glucocorticoid use were 2-3 times that of controls for the calcaneus and radius sites. The differences between glucocorticoid users and controls persisted after adjusting for confounding variables such as age and use of thiazides and estrogens.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584871     DOI: 10.1007/BF00298431

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  16 in total

1.  Bone changes during prednisone treatment.

Authors:  A Deding; L Tougaard; M Krogh Jensen; P Rodbro
Journal:  Acta Med Scand       Date:  1977

Review 2.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

3.  Mineral loss in cortical and trabecular bone during high-dose prednisone treatment.

Authors:  H Rickers; A Deding; C Christiansen; P Rødbro
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

4.  Bone mineral content in patients with rheumatoid arthritis: relationship to low-dose steroid therapy.

Authors:  R C Butler; M W Davie; M Worsfold; C A Sharp
Journal:  Br J Rheumatol       Date:  1991-04

5.  Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study.

Authors:  R F Laan; P L van Riel; L B van de Putte; L J van Erning; M A van't Hof; J A Lemmens
Journal:  Ann Intern Med       Date:  1993-11-15       Impact factor: 25.391

6.  Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Authors:  P Sambrook; J Birmingham; P Kelly; S Kempler; T Nguyen; N Pocock; J Eisman
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

7.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

Authors:  A Verstraeten; J Dequeker
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

8.  Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.

Authors:  K Olgaard; T Storm; N van Wowern; H Daugaard; M Egfjord; E Lewin; L Brandi
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

9.  Bone studies in patients on prolonged systemic corticosteroid therapy for asthma.

Authors:  P A Greenberger; R W Hendrix; R Patterson; J S Chmiel
Journal:  Clin Allergy       Date:  1982-07

10.  The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry.

Authors:  C N de Deuxchaisnes; J P Devogelaer; W Esselinckx; B Bouchez; G Depresseux; C Rombouts-Lindemans; J P Huaux
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

View more
  6 in total

Review 1.  Bone involvement in exogenous hypercortisolism.

Authors:  L Sinigaglia; D Mazzocchi; M Varenna
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

2.  Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register.

Authors:  G Haugeberg; R E Ørstavik; T Uhlig; J A Falch; J I Halse; T K Kvien
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 3.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 4.  Corticosteroid-Induced osteoporosis: detection and management.

Authors:  J D Adachi; A Papaioannou
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  George Ioannidis; Shelley Pallan; Alexandra Papaioannou; Manisha Mulgund; Lorena Rios; Jinhui Ma; Lehana Thabane; Kenneth S Davison; Robert G Josse; Christopher S Kovacs; Nancy Kreiger; Wojciech P Olszynski; Jerilynn C Prior; Tanveer Towheed; Jonathan D Adachi
Journal:  Arch Osteoporos       Date:  2014-02-28       Impact factor: 2.617

6.  Reduced bone mineral density in male Severe Acute Respiratory Syndrome (SARS) patients in Hong Kong.

Authors:  E M C Lau; F W K Chan; D S C Hui; A K L Wu; P C Leung
Journal:  Bone       Date:  2005-09       Impact factor: 4.398

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.